These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 23780645)
1. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. Bambury RM; Teo MY; Power DG; Yusuf A; Murray S; Battley JE; Drake C; O'Dea P; Bermingham N; Keohane C; Grossman SA; Moylan EJ; O'Reilly S J Neurooncol; 2013 Aug; 114(1):149-54. PubMed ID: 23780645 [TBL] [Abstract][Full Text] [Related]
2. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000 [TBL] [Abstract][Full Text] [Related]
3. Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome. Garrett C; Becker TM; Lynch D; Po J; Xuan W; Scott KF; de Souza P PLoS One; 2021; 16(6):e0252614. PubMed ID: 34138894 [TBL] [Abstract][Full Text] [Related]
4. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. Lopes M; Carvalho B; Vaz R; Linhares P J Neurooncol; 2018 Jan; 136(1):173-180. PubMed ID: 29076002 [TBL] [Abstract][Full Text] [Related]
5. A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma Multiforme. Hao Y; Li X; Chen H; Huo H; Liu Z; Tian F; Chai E World Neurosurg; 2019 Aug; 128():e427-e433. PubMed ID: 31042598 [TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy. Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K Oncology; 2019; 97(5):255-263. PubMed ID: 31288238 [TBL] [Abstract][Full Text] [Related]
7. The prognostic effect of neutrophil-to-lymphocyte ratio and De Ritis ratio in glioblastoma multiforme patients. Uzum Y; Salman T; Oflazoglu U; Yildiz Y; Varol U; Aysin M; Kucukzeybek Y; Alacacioglu A; Tarhan MO Bratisl Lek Listy; 2024; 125(8):463-467. PubMed ID: 38989745 [TBL] [Abstract][Full Text] [Related]
8. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. McNamara MG; Lwin Z; Jiang H; Templeton AJ; Zadeh G; Bernstein M; Chung C; Millar BA; Laperriere N; Mason WP J Neurooncol; 2014 Mar; 117(1):147-52. PubMed ID: 24469854 [TBL] [Abstract][Full Text] [Related]
9. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. Han S; Liu Y; Li Q; Li Z; Hou H; Wu A BMC Cancer; 2015 Sep; 15():617. PubMed ID: 26341881 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Indicators of Systemic Inflammatory Responses in Glioblastoma Patients. Kaya V; Yıldırım M; Yazıcı G; Yalçın AY; Orhan N; Güzel A Asian Pac J Cancer Prev; 2017 Dec; 18(12):3287-3291. PubMed ID: 29286221 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma. Yersal Ö; Odabaşi E; Özdemir Ö; Kemal Y Mol Clin Oncol; 2018 Oct; 9(4):453-458. PubMed ID: 30233797 [TBL] [Abstract][Full Text] [Related]
12. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma. Sun J; Ning H; Sun J; Qu X Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433 [TBL] [Abstract][Full Text] [Related]
13. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. Mitsuya K; Nakasu Y; Kurakane T; Hayashi N; Harada H; Nozaki K J Neurosurg; 2017 Aug; 127(2):433-437. PubMed ID: 27911233 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. Inamoto S; Kawada K; Okamura R; Hida K; Sakai Y Int J Colorectal Dis; 2019 Jul; 34(7):1303-1315. PubMed ID: 31177316 [TBL] [Abstract][Full Text] [Related]
15. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas. Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756 [TBL] [Abstract][Full Text] [Related]
16. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Cedrés S; Torrejon D; Martínez A; Martinez P; Navarro A; Zamora E; Mulet-Margalef N; Felip E Clin Transl Oncol; 2012 Nov; 14(11):864-9. PubMed ID: 22855161 [TBL] [Abstract][Full Text] [Related]
17. The Effect of Indicators of Systemic Inflammatory Response on Survival in Glioblastoma Multiforme. Mermut O; Inanc B Turk Neurosurg; 2020; 30(5):658-665. PubMed ID: 32530473 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma. Muriana P; Carretta A; Ciriaco P; Bandiera A; Negri G J Cardiothorac Surg; 2018 Nov; 13(1):119. PubMed ID: 30454002 [TBL] [Abstract][Full Text] [Related]
19. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. Langsenlehner T; Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Gerger A; Pichler M World J Urol; 2015 Nov; 33(11):1661-7. PubMed ID: 25617235 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Grenader T; Waddell T; Peckitt C; Oates J; Starling N; Cunningham D; Bridgewater J Ann Oncol; 2016 Apr; 27(4):687-92. PubMed ID: 26787231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]